Amgen Urges Justices To Leave Enbrel Patent Ruling Alone
Amgen Inc. unit Immunex said Monday that there's no need for the U.S. Supreme Court to review a decision finding the biopharmaceutical company didn't patent the same invention twice for its...To view the full article, register now.
Already a subscriber? Click here to view full article